Latest Breaking News On - Profound medical - Page 6 : comparemela.com

Profound Medical (NASDAQ:PROF) versus BlueRiver Acquisition (NYSE:BLUA) Financial Survey

Profound Medical (NASDAQ:PROF – Get Free Report) and BlueRiver Acquisition (NYSE:BLUA – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, risk, earnings, analyst recommendations and profitability. Earnings & Valuation This table compares Profound […]

United statesSan antonioBritish columbiaBlueriver acquisition corpProfound medicalGet free reportBlueriver acquisitionDriver acquisitionGiven profound medicalMedical corpProfound medical dailyNasdaq profStock comparisonStock analysis

Profound Medical Corp to Post Q1 2025 Earnings of ($0 28) Per Share, Raymond James Forecasts (TSE:PRN)

Profound Medical Corp to Post Q1 2025 Earnings of ($0 28) Per Share, Raymond James Forecasts (TSE:PRN)
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

United statesRaymond jamesMathieu burtnykCompany profileProfound medicalFree reportGet free reportSenior officer mathieu burtnykMedical corpProfound medical daily

Profound Medical Corp (TSE:PRN) to Post Q1 2025 Earnings of ($0 28) Per Share, Raymond James Forecasts

Profound Medical Corp (TSE:PRN) to Post Q1 2025 Earnings of ($0 28) Per Share, Raymond James Forecasts
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

United statesRaymond jamesMathieu burtnykCompany profileProfound medicalFree reportGet free reportSenior officer mathieu burtnykMedical corpProfound medical daily

Raymond James Weighs in on Profound Medical Corp s Q1 2025 Earnings (NASDAQ:PROF)

Profound Medical Corp. (NASDAQ:PROF – Free Report) – Analysts at Raymond James issued their Q1 2025 earnings per share (EPS) estimates for Profound Medical in a report released on Thursday, January 25th. Raymond James analyst R. Sarugaser forecasts that the company will earn ($0.21) per share for the quarter. The consensus estimate for Profound Medical’s […]

United statesRaymond jamesStifel nicolausZweig dimenna associatesInvestment managementAlliance global partnersCompany profileRaymond james associatesRaymond james financial services advisors incRoyal bankProfound medicalFree reportGlobal partnersGet free reportDimenna associatesJames financial services advisors

Post-Hoc Analysis Confirms Consistent Clinical Benefit With Olaparib Plus Abiraterone in HRR-Mutated mCRPC

Olaparib plus abiraterone acetate delayed disease progression and improved outcomes in patients with BRCA-, ATM- and CDK12-mutated mCRPC.

United statesBristol myers squibbBristol myers squibb sanofiMedivation astellasImmunitybio incyteMerck seronoNonagen bioscienceAstellas pharmaJiangsu yahong meditechTelix pharmaceuticalsCarolina urologic research centerAsieris pharmaceuticalsFoundation medicineClarity pharmaceuticalsAragon pharmaceuticalsSpeciality networks